Published in J Virol on September 01, 1993
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J Virol (1994) 5.87
Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J Virol (1995) 5.21
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92
Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol (1996) 3.97
A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding. J Virol (1999) 3.92
Virus maturation by budding. Microbiol Mol Biol Rev (1998) 3.78
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71
Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. J Virol (1994) 3.48
Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol (1994) 3.47
In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. J Virol (1999) 3.34
Proteins related to the Nedd4 family of ubiquitin protein ligases interact with the L domain of Rous sarcoma virus and are required for gag budding from cells. Proc Natl Acad Sci U S A (2001) 3.04
Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras. J Virol (1999) 2.90
Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J Virol (1995) 2.76
Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J Virol (1995) 2.56
Specificity and sequence requirements for interactions between various retroviral Gag proteins. J Virol (1994) 2.50
The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J Virol (1996) 2.31
Membrane vesiculation function and exocytosis of wild-type and mutant matrix proteins of vesicular stomatitis virus. J Virol (1995) 2.23
Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue. J Virol (1998) 2.18
The carboxyl terminus of the human foamy virus Gag protein contains separable nucleic acid binding and nuclear transport domains. J Virol (1996) 1.91
The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly. J Virol (1998) 1.91
Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro. J Virol (1996) 1.85
Effects of nucleocapsid mutations on human immunodeficiency virus assembly and RNA encapsidation. J Virol (1997) 1.83
Nuclear entry and CRM1-dependent nuclear export of the Rous sarcoma virus Gag polyprotein. Proc Natl Acad Sci U S A (2002) 1.76
Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein. J Virol (1996) 1.70
Efficiency and selectivity of RNA packaging by Rous sarcoma virus Gag deletion mutants. J Virol (1994) 1.70
Genetic determinants of Rous sarcoma virus particle size. J Virol (1998) 1.67
Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions. J Virol (2001) 1.55
Particle size determinants in the human immunodeficiency virus type 1 Gag protein. J Virol (1998) 1.48
Sequence requirements for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles. J Virol (1995) 1.44
A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J Virol (1996) 1.43
Viral DNA synthesis defects in assembly-competent Rous sarcoma virus CA mutants. J Virol (2001) 1.39
Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera. J Virol (2000) 1.36
Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release. J Virol (1998) 1.32
Mutations in the Ty3 major homology region affect multiple steps in Ty3 retrotransposition. J Virol (1996) 1.30
Human immunodeficiency virus type 1 capsid formation in reticulocyte lysates. J Virol (1996) 1.27
Biochemical characterization of rous sarcoma virus MA protein interaction with membranes. J Virol (2005) 1.27
Identification of retroviral late domains as determinants of particle size. J Virol (1999) 1.25
Type D retrovirus capsid assembly and release are active events requiring ATP. J Virol (1998) 1.22
U1 small nuclear ribonucleoprotein and splicing inhibition by the rous sarcoma virus negative regulator of splicing element. J Virol (1999) 1.22
RNA dimerization defect in a Rous sarcoma virus matrix mutant. J Virol (2000) 1.18
Both the PPPY and PTAP motifs are involved in human T-cell leukemia virus type 1 particle release. J Virol (2004) 1.17
Lysines close to the Rous sarcoma virus late domain critical for budding. J Virol (2004) 1.16
Separate assembly and transport domains within the Gag precursor of Mason-Pfizer monkey virus. J Virol (1999) 1.13
Directionality of nucleocytoplasmic transport of the retroviral gag protein depends on sequential binding of karyopherins and viral RNA. Proc Natl Acad Sci U S A (2010) 1.11
The role of overlapping U1 and U11 5' splice site sequences in a negative regulator of splicing. RNA (1999) 1.09
Analysis of bovine leukemia virus gag membrane targeting and late domain function. J Virol (2002) 1.07
Conditions for copackaging rous sarcoma virus and murine leukemia virus Gag proteins during retroviral budding. J Virol (1999) 1.07
Altered Rous sarcoma virus Gag polyprotein processing and its effects on particle formation. J Virol (1997) 1.05
Ty3 capsid mutations reveal early and late functions of the amino-terminal domain. J Virol (2007) 1.03
Genetic analysis of interactions between Gag proteins of Rous sarcoma virus. J Virol (1997) 1.01
The gag domains required for avian retroviral RNA encapsidation determined by using two independent assays. J Virol (1999) 0.99
In vivo interference of Rous sarcoma virus budding by cis expression of a WW domain. J Virol (2002) 0.95
Basic residues of the retroviral nucleocapsid play different roles in gag-gag and Gag-Psi RNA interactions. J Virol (2004) 0.93
Intermolecular interactions between retroviral Gag proteins in the nucleus. J Virol (2007) 0.92
HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (2002) 0.90
Characterization of a myristoylated, monomeric HIV Gag protein. Virology (2009) 0.89
Transport and processing of the Rous sarcoma virus Gag protein in the endoplasmic reticulum. J Virol (1996) 0.86
Alterations in the MA and NC domains modulate phosphoinositide-dependent plasma membrane localization of the Rous sarcoma virus Gag protein. J Virol (2013) 0.86
Assembly and processing of human immunodeficiency virus Gag mutants containing a partial replacement of the matrix domain by the viral protease domain. J Virol (2000) 0.82
Mechanistic differences between nucleic acid chaperone activities of the Gag proteins of Rous sarcoma virus and human immunodeficiency virus type 1 are attributed to the MA domain. J Virol (2014) 0.80
Insertion of capsid proteins from nonenveloped viruses into the retroviral budding pathway. J Virol (2001) 0.77
Arenavirus budding resulting from viral-protein-associated cell membrane curvature. J R Soc Interface (2013) 0.76
Fluorosomes: fluorescent virus-like nanoparticles that represent a convenient tool to visualize receptor-ligand interactions. Sensors (Basel) (2013) 0.76
Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly. J Virol (2016) 0.76
Nucleotide sequence of Rous sarcoma virus. Cell (1983) 17.80
Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell (1989) 9.68
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
Point mutants of Moloney murine leukemia virus that fail to package viral RNA: evidence for specific RNA recognition by a "zinc finger-like" protein sequence. Proc Natl Acad Sci U S A (1988) 6.44
Characterization of Moloney murine leukemia virus mutants with single-amino-acid substitutions in the Cys-His box of the nucleocapsid protein. J Virol (1989) 5.47
Rous sarcoma virus nucleic acid-binding protein p12 is necessary for viral 70S RNA dimer formation and packaging. J Virol (1986) 4.85
An avian oncovirus mutant (SE 21Q1b) deficient in genomic RNA: biological and biochemical characterization. Cell (1978) 4.66
Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells. J Virol (1989) 4.60
Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src. J Virol (1991) 4.25
An N-terminal peptide from p60src can direct myristylation and plasma membrane localization when fused to heterologous proteins. Nature (1985) 4.06
Mutations in Rous sarcoma virus nucleocapsid protein p12 (NC): deletions of Cys-His boxes. J Virol (1988) 3.65
Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43
Properties of a ribonucleoprotein particle isolated from Nonidet P-40-treated Rous sarcoma virus. J Virol (1972) 3.25
Assembly of gag-beta-galactosidase proteins into retrovirus particles. J Virol (1990) 2.99
Characterization of a Rous sarcoma virus mutant defective in packaging its own genomic RNA: biochemical properties of mutant TK15 and mutant-induced transformants. J Virol (1984) 2.95
Point mutations in the proximal Cys-His box of Rous sarcoma virus nucleocapsid protein. J Virol (1990) 2.93
Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation. J Gen Virol (1992) 2.89
Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology (1992) 2.88
Transport and assembly of gag proteins into Moloney murine leukemia virus. J Virol (1990) 2.81
It is Rous sarcoma virus protein P12 and not P19 that binds tightly to Rous sarcoma virus RNA. J Mol Biol (1984) 2.57
Specific and saturable binding of pp60v-src to plasma membranes: evidence for a myristyl-src receptor. Cell (1989) 2.53
Avian retroviral RNA encapsidation: reexamination of functional 5' RNA sequences and the role of nucleocapsid Cys-His motifs. J Virol (1993) 2.52
Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc Natl Acad Sci U S A (1991) 2.28
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Identification of a 32K plasma membrane protein that binds to the myristylated amino-terminal sequence of p60v-src. Nature (1990) 2.09
Characteristics and regulation of interaction of avian retrovirus pp12 protein with viral RNA. J Virol (1983) 1.94
Specificity of Rous sarcoma virus nucleocapsid protein in genomic RNA packaging. J Virol (1992) 1.92
The src protein contains multiple domains for specific attachment to membranes. Mol Cell Biol (1990) 1.90
An avian oncovirus mutant deficient in genomic RNA: characterization of the packaged RNA as cellular messenger RNA. Virology (1979) 1.89
Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers. J Virol (1991) 1.48
Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells. J Virol (1990) 1.36
Transforming activity of ras proteins translocated to the plasma membrane by a myristoylation sequence from the src gene product. Oncogene (1988) 1.17
A defective retrovirus particle (SE21Q1b) packages and reverse transcribes cellular RNA, utilizing tRNA-like primers. J Virol (1984) 0.97
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92
DNA content, kinetic complexity, and the ploidy question in Candida albicans. Mol Cell Biol (1982) 4.64
Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein. J Virol (1997) 4.08
Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol (1996) 3.97
Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci U S A (2000) 3.83
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71
Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43
Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11
WW domains and retrovirus budding. Nature (1996) 3.10
Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras. J Virol (1999) 2.90
Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J Virol (1995) 2.76
Repetitive DNA of Candida albicans: nuclear and mitochondrial components. J Bacteriol (1984) 2.52
Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol (1993) 2.40
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue. J Virol (1998) 2.18
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol (1995) 1.93
Intracellular trafficking of the UL11 tegument protein of herpes simplex virus type 1. J Virol (2001) 1.90
Circular mitochondrial genome of Candida albicans contains a large inverted duplication. J Bacteriol (1985) 1.84
Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein. J Virol (1996) 1.70
Efficiency and selectivity of RNA packaging by Rous sarcoma virus Gag deletion mutants. J Virol (1994) 1.70
Genetic determinants of Rous sarcoma virus particle size. J Virol (1998) 1.67
Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions. J Virol (2001) 1.55
Particle size determinants in the human immunodeficiency virus type 1 Gag protein. J Virol (1998) 1.48
Recent advances and remaining problems in HIV assembly. AIDS (1998) 1.46
A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J Virol (1996) 1.43
The membrane-binding domain of the Rous sarcoma virus Gag protein. J Virol (1996) 1.39
Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera. J Virol (2000) 1.36
Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells. J Virol (1990) 1.36
Repositioning basic residues in the M domain of the Rous sarcoma virus gag protein. J Virol (2000) 1.33
Alterations in the transport and processing of Rous sarcoma virus envelope glycoproteins mutated in the signal and anchor regions. J Cell Biochem (1983) 1.31
Identification of retroviral late domains as determinants of particle size. J Virol (1999) 1.25
Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport. J Cell Biol (1986) 1.21
Isolation of virus-neutralizing RNAs from a large pool of random sequences. Proc Natl Acad Sci U S A (1995) 1.18
RNA dimerization defect in a Rous sarcoma virus matrix mutant. J Virol (2000) 1.18
Expression of the Rous sarcoma virus env gene from a simian virus 40 late-region replacement vector: effects of upstream initiation codons. J Virol (1987) 1.18
Molecular cloning of the Mason-Pfizer monkey virus genome: characterization and cloning of subgenomic fragments. Virology (1985) 1.08
Conditions for copackaging rous sarcoma virus and murine leukemia virus Gag proteins during retroviral budding. J Virol (1999) 1.07
Transport and processing of the Rous sarcoma virus Gag protein in the endoplasmic reticulum. J Virol (1996) 0.86
The major site of phosphorylation within the Rous sarcoma virus MA protein is not required for replication. J Virol (1998) 0.84
Insertion of capsid proteins from nonenveloped viruses into the retroviral budding pathway. J Virol (2001) 0.77
Automation and validation of micronucleus detection in the 3D EpiDerm™ human reconstructed skin assay and correlation with 2D dose responses. Mutagenesis (2014) 0.77
Esophagoscopy. An analysis of two hundred cases. Med Ann Dist Columbia (1966) 0.75